asivatrep   Click here for help

GtoPdb Ligand ID: 9621

Synonyms: Example 230 [US7858621] | PAC-14028
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Asivatrep (PAC-14028) is an antagonist of the transient receptor potential vanilloid type 1 (TRPV1) channel, developed by AmorePacific for anti-inflammatory potential in refractory dermatoses [2]. It is claimed as example 230 in patent US7858621 [1]. PAC-14028 is administered topically for skin inflammation.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 96.54
Molecular weight 491.13
XLogP 4.4
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCCc1nc(ccc1C=CC(=O)NC(c1cc(F)c(c(c1)F)NS(=O)(=O)C)C)C(F)(F)F
Isomeric SMILES CCCc1nc(ccc1/C=C/C(=O)N[C@@H](c1cc(F)c(c(c1)F)NS(=O)(=O)C)C)C(F)(F)F
InChI InChI=1S/C21H22F5N3O3S/c1-4-5-17-13(6-8-18(28-17)21(24,25)26)7-9-19(30)27-12(2)14-10-15(22)20(16(23)11-14)29-33(3,31)32/h6-12,29H,4-5H2,1-3H3,(H,27,30)/b9-7+/t12-/m1/s1
No information available.
Summary of Clinical Use Click here for help
A Phase 3 clinical study evaluating PAC-14028 vs. atopic dermatitis is underway (see NCT02965118). Phase 2 studies for rosacea, seborrheic dermatitis and skin pruritus have been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02965118 CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis Phase 3 Interventional Amorepacific Corporation